TTrialPathMatch Me to Trials
← Back to trials
RecruitingMild Cognitive Impairment

CBD for Individuals at Risk for Alzheimer's Disease

Eligible age

55–85 yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This is a double-blind, randomized controlled trial designed to test the effects of cannabidiol (CBD) on validated biomarkers of Alzheimer's disease (AD) progression, and behavioral, neurocognitive, and clinical measures, with putative mechanisms of action.

Sponsor: University of Colorado, Denver

You may qualify if…

  • ✓ 1. Must be between the ages of 55 - 85 and provide valid informed consent.
  • ✓ 2. Participant must receive a diagnosis of Mild Cognitive Impairment after a careful cognitive and functional evaluation by a clinician, or have symptoms of Mild Cognitive Impairment as determined by the study physician.
  • ✓ 3. Functional Activities Questionnaire (FAQ) score of 8 or less and self-reported ability to function independently.
  • ✓ 4. Montreal Cognitive Assessment (MoCa) score is ≤ 25
  • ✓ 5. Participant must have a CDR score of .5 or 1 on the Clinical Dementia Rating scale (CDR), which includes an assessment of function and is often used to distinguish MCI from dementia. A score of 0.5 indicates mild cognitive impairment but not dementia and a score of 1 indicates mild-to-moderate cognitive impairment.
  • ✓ 6. Must have an informant that will be utilized over the course of the 24 week study (must be the same person for all CDR assessments completed via phone).
  • ✓ 7. Participant must pass a test of consent comprehension
  • ✓ 8. Must be interested in using CBD to help with cognitive function

You may not qualify if…

  • ✕ 1. Any other central nervous system (CNS) disease that would be expected to affect cognition, Parkinson's disease, multiple sclerosis.
  • ✕ 2. History of brain injury resulting in current memory loss symptoms (e.g., concussion with significant loss of consciousness)
  • ✕ 3. Any significant systemic illness or unstable medical condition
  • ✕ 4. Current use of Parkinson's medications, antipsychotic medications, anti-seizure medications, or anticholinergic medications
  • ✕ 5. Current or lifetime diagnosis of a schizophrenia spectrum disorder, psychotic disorder, bipolar disorder type I \& II, cluster B personality disorders (antisocial, borderline, narcissistic, histrionic), eating disorders, as defined by the DSM-5-TR
  • ✕ 6. Participation in other clinical studies involving neuropsychological measures being collected more than one time per year.
  • ✕ 7. Reported use of other drugs (cocaine, opiates, methamphetamine, MDMA) in the past 60 days or test positive on a urine test for those drugs of abuse at baseline.
  • ✕ 8. Report using more than 150mg of cannabis edible products per week.

Where it's recruiting

Colorado

Aurora

Source: ClinicalTrials.gov · NCT05822362 · last updated 2026-06-15

CBD for Individuals at Risk for Alzheimer's Disease · TrialPath